![]() ![]() ![]() It's unusual, and I'd say a fraction of them are actually practice changing. How surprising is it to see so many therapies in one disease state-approved in one month? “So, it's kind of a mixed bag.”ĬURE®: By all counts, the FDA approved seven therapies to treat non-small cell lung cancer back in May. “Some of them are a little head scratching based on the standards that have been used in the past and some of them are, you know, the real deal we're quite excited about,” Burns, a medical oncologist at UPMC Hillman Cancer Center, said in a recent interview with CURE®. The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual - and only a fraction of them are considered practice-changing, according to Dr. ![]()
0 Comments
Leave a Reply. |